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Measurable Residual Disease at Induction Redeﬁnes Partial
Response in Acute Myeloid Leukemia and Stratiﬁes Outcomes
in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman, Robert K. Hills, Paul Virgo, Naeem Khan, Steve Couzens, Richard Dillon, Amanda Gilkes,
Laura Upton, Ove Juul Nielsen, James D. Cavenagh, Gail Jones, Asim Khwaja, Paul Cahalin, Ian Thomas, David
Grimwade,† Alan K. Burnett, and Nigel H. Russell
A B S T R A C T
Purpose
We investigated the effect on outcome of measurable or minimal residual disease (MRD) status
after each induction course to evaluate the extent of its predictive value for acute myeloid leukemia
(AML) risk groups, including NPM1 wild-type (wt) standard risk, when incorporated with other
induction response criteria.
Methods
As part of the NCRI AML17 trial, 2,450 younger adult patients with AML or high-risk myelodysplastic
syndrome had prospective multiparameter ﬂow cytometric MRD (MFC-MRD) assessment. After
course 1 (C1), responses were categorized as resistant disease (RD), partial remission (PR), and
complete remission (CR) or complete remission with absolute neutrophil count , 1,000/mL or
thrombocytopenia , 100,000/mL (CRi) by clinicians, with CR/CRi subdivided by MFC-MRD assay
into MRD+ andMRD2. Patients without high-risk factors, including Flt3 internal tandem duplication
wt/2NPM1-wt subgroup, received a second daunorubicin/cytosine arabinoside induction; course 2
(C2) was intensiﬁed for patients with high-risk factors.
Results
Survival outcomes from PR and MRD+ responses after C1 were similar, particularly for good- to
standard-risk subgroups (5-year overall survival [OS], 27% RD v 46% PR v 51% MRD+ v 70%
MRD2; P , .001). Adjusted analyses conﬁrmed signiﬁcant OS differences between C1 RD versus
PR/MRD+ but not PR versus MRD+. CRi after C1 reduced OS in MRD+ (19% CRi v 45% CR; P =
.001) patients, with a smaller effect after C2. The prognostic effect of C2 MFC-MRD status (relapse:
hazard ratio [HR], 1.88 [95%CI, 1.50 to 2.36], P, .001; survival: HR, 1.77 [95%CI, 1.41 to 2.22], P,
.001) remained signiﬁcant when adjusting for C1 response. MRD positivity appeared less dis-
criminatory in poor-risk patients by stratiﬁed analyses. For the NPM1-wt standard-risk subgroup, C2
MRD+ was signiﬁcantly associated with poorer outcomes (OS, 33% v 63% MRD2, P = .003;
relapse incidence, 89% when MRD+ $ 0.1%); transplant beneﬁt was more apparent in patients
withMRD+ (HR, 0.72; 95%CI, 0.31 to 1.69) than thosewithMRD2 (HR, 1.68 [95%CI, 0.75 to 3.85];
P = .16 for interaction).
Conclusion
MFC-MRD can improve outcome stratiﬁcation by extending the deﬁnition of partial response after
ﬁrst induction and may help predict NPM1-wt standard-risk patients with poor outcome who beneﬁt
from transplant in the ﬁrst CR.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology
INTRODUCTION
In acute myeloid leukemia (AML), failure to
achieve morphologic complete remission (CR)
after a ﬁrst cycle of induction in previously un-
treated patients is an established independent
prognostic factor from earlier studies.1-3 Thus,
morphologic response at this time point is often
incorporated with genetic and pretreatment clin-
ical parameters to guide further therapy,4 including
second induction courses, choice of consolidation,
and whether intensiﬁcation from allogeneic stem-
cell transplantation (SCT) may be appropriate in
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otherwise intermediate-risk patients. Despite morphologic response
criteria being standard, a different approach for measuring response
has been proposed5,6 owing to the independent prognostic value
from measurable or minimal residual disease (MRD) assays when
discrepant with morphology,7-9 or in CR10-12 and the equivalent
poor outcomes between MRD positivity and active-disease pre-
myeloablative SCT.13,14
Studies have shown the prognostic value of MRD monitoring
by polymerase chain reaction (PCR) for patients with validated
molecular targets, usually after two courses of chemotherapy.11,12,15
Multiparametric ﬂow cytometry MRD (MFC-MRD) may identify,
as early as after course 1 (C1), patients with a poorer response
despite achieving CR and is an assay that can be applied across AML
genetic subgroups.12,16-20 There are, however, insufﬁcient data to as-
certain the relative prognostic effect of MFC-MRD positivity in CR
post-C1 compared with morphologic active disease; it is feasible that
the outcomes of patients with detectable MRD resemble those of
refractory patients who achieve the cytoreduction criteria for a mor-
phologic partial remission (PR).21,22 Evaluating this will help reﬁne
which response categories are themost useful prognostic surrogate end
points to assess effectiveness of the ﬁrst induction course.
It is also uncertain for patients who complete a second
chemotherapy course whether the quality of response after C1,
with inclusion of MFC-MRD assessment, adds prognostic in-
formation to CR-MRD status after course 2 (C2). The value of
MFC-MRD status to differentiate outcome at either time point is
likely to be heterogeneous between established risk subgroups due
to disease, treatment, and assay factors, but the extent of this has
not been established.
Treatment decisions, including predicting the beneﬁt of SCT, are
particularly challenging for the standard-risk subgroup. MFC-MRD
assays are most likely to inﬂuence therapeutic choices for NPM1-wild
type (wt) patients of standard risk, following data indicating post-
induction reverse transcriptase, quantitative PCR (RT-qPCR) of
blood-mutated transcripts reliably predicts outcome for patients with
NPM1 mutation.23,24 Thus, there is a speciﬁc need to deﬁne the
usefulness of MFC-MRD for risk stratiﬁcation in this subgroup.
In this study, we aimed to determine the prognostic effect of
MFC-MRD measurement incorporated into response assessment
after induction courses for the different risk subgroups, including
NPM1-wt patients at standard risk, in a large cohort of younger
patients with AML who had undergone intensive treatment in the
National Cancer Research Institute (NCRI) AML17 trial.
METHODS
Patients
Patients were enrolled in the NCRI AML17 trial (ISRCTN Registry
No. 55675535) from April 6, 2009, to December 31, 2014. A list of
treatments is provided in Appendix Fig. A1 (online only).
The AML17 protocol was designed primarily for younger patients,
generally age , 60 years. Patients with high-risk myelodysplastic syn-
drome, which was deﬁned as . 10% marrow blasts at diagnosis, and
secondary AML were eligible. Patients with acute promyelocytic leukemia
were not included in this MRD study. After ﬁrst induction, patients were
deﬁned by risk of relapse, using a validated score comprising cytogenetics,
WBC count, age, secondary disease, morphologic response to C125,26 and
FLT-3 internal tandem duplication(ITD)/NPM1 mutation status.
Morphologic-based response criteria were as follows: (1) CR, , 5%
blasts in a cellular bone marrow with count recovery, CRi if 5% blasts but
best response was with neutropenia , 1,000/mL or thrombocytope-
nia, 100,000/mL; (2) partial remission (PR), decrease of pretreatment bone
marrow blast percentage by at least 50% to 5% to 15% in a cellular marrow
(hematologic recovery not required)1; and (3) resistant disease (RD),
. 15%marrow blasts (patients surviving at least 7 days after completion of
treatment). Responses were classiﬁed by centers.
Patients designated as favorable or at standard risk received the
second daunorubicin/cytosine arabinoside course and were then ran-
domized to receive either 1 or 2 courses of high-dose cytosine arabinoside.
High-risk patients were offered a randomization between FLAG-Ida or
daunorubicin/clofarabine with the intention of eventually proceeding to
allogeneic stem-cell transplantation (SCT). FLT3-ITD mutant patients
were directed to the lestaurtinib randomization until 2012.
The trial was sponsored by Cardiff University, approved by Wales-
REC3 and conducted in accordance with the Declaration of Helsinki.
Multiparameter Flow Cytometry Detection of MRD
Samples for multiparameter ﬂow cytometry (MFC)-MRD were
requested at baseline (bone marrow and/or blood) and following each
course (bone marrow). A summary of sample logistics and processing is
provided in the Data Supplement. MFC-MRD analysis was performed
centrally, using standardized gating strategy that screened for “different-
from-normal” leukemia-associated-immunophenotypes (LAIPs) on blasts
pretreatment and tracked these (approximately 0.02% to 0.05% sensitivity
thresholds) but also applied the different-to-normal approach in follow-up
samples to detect changes in blast LAIPs (approximately 0.05% to 0.1%
sensitivity threshold). In this study, only samples for which there were
pretreatment LAIPs to monitor could be reported as MFC-MRD negative,
whereas samples with any level of MRD detected above a diagnostic LAIP
or different-from-normal follow-up LAIP threshold were reported as
MFC-MRD positive. Clinicians were not informed of MFC-MRD results.
Statistical Analysis
All end points were based on the revised criteria of the International
Working Group for Diagnosis.21 Survival percentages were calculated using
the Kaplan-Meier method with cumulative incidence of relapse calculated
using competing-risks methodology. Baseline characteristics were com-
pared using x2 or Mantel-Haenszel tests, with continuous variables
compared using the Wilcoxon rank-sum test. Time-to-event outcomes
were compared using log-rank tests and Cox regression. Outcomes are
reported as effect sizes with 95% conﬁdence intervals; signiﬁcance was set
at P , .05. Stratiﬁed analyses used stratiﬁed log-rank tests and are dis-
played as forest plots with tests for interaction using standard method-
ology.27 Comparison of transplantation versus not was analyzed using the
method ofMantel and Byar tomitigate immortal time bias. Median follow-
up for survival was 39.0 months (range, 1.0 to 80.5 months).
RESULTS
Induction Response by Morphology and MFC-MRD:
Patient Characteristics
Between 2009 and 2014, 6,539 samples (bone marrow [BM] or
peripheral blood at diagnosis, BM post-treatment courses) from
2,450 patients with non-acute promyelocytic leukemia recruited to
AML17 were prospectively analyzed for MFC-MRD (Appendix Fig
A2, online only). Among patients in CR post-C1, the presence of
MRD data were associated with secondary AML, and the absence of
an NPM1 mutation (reﬂecting the prioritizing of BM for RT-qPCR
monitoring of NPM1 mutations23 during the second phase of the
trial); survival at 5 years was 52% (with MRD data) versus 50%
2 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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(withoutMRDdata). In adjusted analyses, the presence ofMRDdata
was not associated with survival (hazard ratio [HR], 0.99 [95% CI,
0.84 to 1.16]; P = .9).
Post-C1, 1,443 patients contributed data; 420 were refractory
by morphology (n = 197 RD; n = 223 PR) and 1,023 (70.9%)
achieved CR/CRi with MFC-MRD data (n = 446 MFC-MRD
negative [MRD2]; n = 577 MFC-MRD positive [MRD+]). After
C2, 806 patients were in CR/CRi with MFC-MRD data (n = 503
MRD2; n = 303 MRD+).
The clinical characteristics of patients according to response post-
C1 andMRD status for patients in CR/CRi post-C1 or C2 are listed in
Table 1. There was a signiﬁcant association between responses post-C1
or C2 and cytogenetic group; however, count recovery post-C1 was
not signiﬁcantly associated with MRD after either course.
Outcome Comparison for Morphologic Response and
MFC-MRD Status After C1
We evaluated overall survival (OS) by C1 response status.
Five-year OS for all enrolled in AML17 excluding early deaths was
52% for those achieving CR/CRi versus 31% for refractory patients
(P , .001). MRD status in CR/CRi versus PR or RD further dif-
ferentiated 5-year survival outcomes (Fig 1A). A PR or MRD+
response gave intermediate survival at 5 years. Survival rates
appeared equivalent between these two responses for the patients at
good or standard risk; 5-year OS for MRD2 versus MRD+ versus
PR versus RD were 63% versus 44% versus 35% versus 24%, re-
spectively, for all patients; 70% versus 51% versus 46% versus 27%,
respectively, when patients at poor risk were excluded (Fig 1B); and
66% versus 49% versus 46% versus 30%, respectively, for standard
risk alone (P , .001 for all analyses; Fig 1C). Similar results were
observed for survival censored at SCT (Fig 1D; Fig A3A, online only)
and also for NPM1-wt patients at standard risk (Fig A3B and A3C).
Adjusted analyses conﬁrmed signiﬁcant survival differences
between RD and PR/MRD+ but not between PR and MRD+ for
patients at good or standard risk (RD v PR/MRD+: OS HR, 2.28
[95% CI, 1.38 to 3.75]; P , .001; PR vs MRD+: HR, 1.32; P = .4)
and for NPM1-wt patients at standard risk (RD v PR/MRD+: OS
HR, 2.13 [95% CI, 1.21 to 3.75]; P = .008; PR vs MRD+: HR, 1.18,
P = .6). Results were similar when censored at SCT (Table 2).
0 1 2 3 4 5
25
50
75
100
A
OS
 (%
)
Years Since Entry
63%
44%
35%
24%
No. at risk:
CR/CRi, MRD− 446 373 272 192 122 71
CR/CRi, MRD+ 575 451 272 173 97 41
PR 197 121 72 47 31 11
RD 221 104 56 29 16 10
No.
Patients
No.
Events
CR/CRi, MRD− 446 139
CR/CRi, MRD+ 575 273
PR 197 112
RD 221 151
P < ·00001
B
0 1 2 3 4 5
25
50
75
100
OS
 (%
)
Years Since Entry
70%
51%
46%
27%
No. at risk:
CR/CRi, MRD− 344 306 225 161 104 62
CR/CRi, MRD+ 358 300 190 120 69 32
PR 59 42 28 22 15 5
RD 55 28 16 5 3 2
No.
Patients
No.
Events
CR/CRi, MRD− 344 83
CR/CRi, MRD+ 358 141
PR 59 26
RD 55 37
P < ·00001
C
0 1 2 3 4 5
25
50
75
100
OS
 (%
)
Years Since Entry
66% 
49% 
46% 
30% 
No. at risk:
CR/CRi, MRD− 253 221 160 114 69 41
CR/CRi, MRD+ 267 219 133 91 49 22
PR 42 31 22 17 12 4
RD 37 21 13 113
No.
Patients
No.
Events
CR/CRi, MRD− 253 69
CR/CRi, MRD+ 267 111
PR 42 18
RD 37 24
P < ·00001
D
0 1 2 3 4 5
25
50
75
100
OS
 (%
)
Years Since Entry
77%
53%
62%
25%
No. at risk:
CR/CRi, MRD− 253 170 110 70 43 24
CR/CRi, MRD+ 266 165 69 45 20 9
PR 42 17 12
RD 37
479
00024
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
No.
Patients
No.
Events
CR/CRi, MRD− 253 39
CR/CRi, MRD+ 266 67
PR 42 9
RD 37 16
P < ·00001
Fig 1. Overall survival (OS) according to response status after course 1. (A) All patients. (B) Patients at good and standard risk (patients known to be at poor risk excluded).
(C) Patients at standard risk. (D) OS for patients at standard risk censored at allogeneic stem-cell transplantation. CR, complete remission; CRi, complete remission with
absolute neutrophil count , 1,000/mL or thrombocytopenia , 100,000/mL; MRD, measurable residual disease; PR, partial remission; RD, resistant disease.
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Thus, the prognostic effect from morphologic response cri-
teria after ﬁrst induction was restricted to RD in the good and
standard-risk subgroups whenMFC-MRD status was incorporated
into response assessment.
Only 25 patients were refractory by morphology post-C1 but
MRD2 (n = 22 PR; n = 3 RD) with 61% 3-year and 49% 5-year
OS. Seven of 577 MRD+ patients were in morphologic CR but
had $ 5% aberrant blasts by MFC (range, 5.4% to 38%); six died
within 2 years, with one patient alive at 58.6 months.
Relative Prognostic Effect of MFC-MRDAfter C1 and C2
by Genetic/Risk Score Subgroup
In AML17, patients received two courses of induction regardless
of remission status after C1, but C2 differed for patients designated
as poor risk by trial risk score. Analyses of survival and relapse by
MFC-MRD status of patients with disease in CR/CRi for C1 (n =
1,010) and C2 (n = 803) were performed stratiﬁed by cytogenetic28
and trial risk subgroups (Fig 2; Appendix Fig A4, online only) to
investigate the relative prognostic effect from clearance of blasts
below MFC-MRD detection threshold at either of these response
assessment time points. There was some evidence that the beneﬁt
fromMFC-MRD negativity on OSwas lower in patients at poor risk
compared with other subgroups with the NCRI AML17 treatment
schedule (P for test for trend = .01 for C1; P = .05 for C2). Overall,
MFC-MRD status appeared more prognostic for relapse and OS at
C2 (relapse: HR, 1.88 [95%CI, 1.50 to 2.36], P, .001; survival: HR,
1.77 [95% CI, 1.41 to 2.22], P , .001) than C1 (relapse: HR, 1.70
[95%CI, 1.40 to 2.06], P, .001; survival: HR, 1.50 [95%CI, 1.23 to
1.84], P , .001), although this difference diminished when C1
analysis was restricted to patients who received C2 and survived at
least 30 days post-C2 (relapse: HR, 1.80 [95% CI, 1.49 to 2.18], P,
.001; survival:, HR, 1.87 [95% CI, 1.52 to 2.29], P , .001).
Outcomes of Combined C1 Response Status and C2
MFC-MRD Status
In patients with response/MFC-MRD data for both C1 and C2
time points (n = 693), C2 MFC-MRD positivity remained signiﬁcant
on OS and relapse when adjusting for C1 response (5-year survival:
HR, 1.79 [95%CI, 1.38 to 2.32], P, .001; relapse: HR, 1.52 [95%CI,
1.18 to 1.96], P= .001; Fig 3). A total of 24 patients converted fromC1
MRD2 to C2 MRD+, with a particularly poor prognosis (n = 15
relapses; n = 13 deaths); one had adverse risk cytogenetics and ﬁve had
Flt3-ITD mutations (Appendix Table A1). Patients who were MRD2
at both C1 and C2 had the best outcome (n = 224; n = 76 relapses; n =
58 deaths); of these, 80.8% were at good or standard risk and 26.3%
were NPM1-wt patients at standard risk (Appendix Table A2).
MRD Status Combined With Peripheral Count Recovery
We examined the additional prognostic effect of combining
MRD status with response by peripheral count recovery post-C1 and
C2 (Appendix Table A3). The frequencies of CRi as best response in
the total cohort were similar in MRD+ versus MRD2 patients post-
C1 (9.3% v 9.6%) and C2 (13.1% v 12.0%); CRi frequencies were
not relatively increased in theNPM1-wt standard-risk subgroup. C1
CRi was associated with signiﬁcantly decreased 5-year OS for total
(39% v 53%; P= .002) and inMRD+ (19% v 45%; P= .001), but not
for MRD2 patients. MRD+ NPM1-wt patients at standard risk in
CRi also had a lower OS at 5 years (25% v 48%; P = .4), although
difference was not signiﬁcant. The effect of CRi versus CR was
smaller post-C2, although outcomes were still worse in CRi/MRD+
patients. The reduced survival associated with CRi was not due to
increased relapse.
Outcome by MFC-MRD Status for NPM1-wt Patients at
Standard Risk
Because it is possible that the most appropriate MFC-MRD
cutoff level for discriminating outcome may differ among AML
genetic subgroups, we compared the 5-year cumulative incidence
of relapse for C1 MRD2 versus MRD+ , 0.1% versus MRD+
$ 0.1% by our assay in core binding factor (CBF)-AML and NPM1-
mutated as well as NPM1wt standard-risk patients. For patients
with CBF-AML and NPM1 mutation, post-C1 MRD+ at any level
(, 0.1% or$ 0.1%) signiﬁcantly increased relapse (Appendix Fig
A5, online only). However, in the NPM1-wt standard-risk sub-
group, low-levelMRD+ (, 0.1%) post-C1 did not alter relapse risk
compared with MRD2 but was associated with a higher cumu-
lative incidence of relapse (CIR) when detected post-C2 (Fig 4A).
MRD+ levels of $ 0.1% detected in 35% and 13% NPM1-wt
patients at standard risk post-C1 and post-C2, respectively, pre-
dicted a high probability of relapse (C1 3-year CIR, 68%; C2 CIR,
89%). MRD status after second induction was also signiﬁcantly
prognostic for survival: 33% for any level of MRD positivity versus
63% for MRD2 at 5 years (3 years, 47% v 69%; P = .003; Fig 4B).
Of the 204 NPM1-wt patients at standard risk who had C2
MRD data, 83 had an allograft (n = 44 in ﬁrst CR: n = 29 MRD2
and n = 15 MRD+). When survival was censored at any SCT, rates
of 5-year OS were 35% versus 88% (3 years, 47% v 88%; P, .001;
Appendix Fig A6, online only).
We next investigated the effect of SCT in ﬁrst CR according to
C2 MRD status in Mantel-Byar analyses. Although numbers were
small, results suggested that transplant might be considered in
MRD+ (HR, 0.72; 5% CI, 0.31 to 1.69) but not MRD2 patients
(HR, 1.68 [95% CI, 0.75 to 3.85]; P for interaction = .16; Fig 4C).
DISCUSSION
Response to induction therapy is a powerful prognostic indicator
in AML. There are, however, differing practices for the imple-
mentation of technologies that measure residual leukemia to assess
response. Flow cytometry is often used to support the deﬁnition of
CR by morphology; those centers with access to experienced
laboratories, including some trial groups, have extended its use to
deﬁne CR without MRD.5 It has been reported that outcomes after
myeloablative SCT for patients with pretransplant MFC-MRD
, 5% resemble those with at least 5% blasts by morphology.13
This and the similar event-free survival observed in approximately
80 pediatric patients with MRD positivity after ﬁrst induction,
whether , 5% or $ 5% blasts by morphology,7 suggest that di-
chotomizing patients by a 5% blast CR cutoff fails to capture some
prognostic information. Our results conﬁrm this. By incorporating
MFC-MRD with established response criteria of PR and RD,
distinct prognostic groups for 5-year survival emerge after the ﬁrst
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course of standard induction. Importantly, the response subgroup
with intermediate outcome comprises patients on either side of the
current CR blast threshold, those with MRD positivity in CR and
those who are refractory but clinically classiﬁed as a PR; both
responses are associated with similar 5-year survival, particularly in
patients otherwise allocated as belonging to good- or standard-risk
subgroups. This is also the case when PR is deﬁned by European
LeukemiaNet criteria5,21(Appendix Fig A7, online only). From this,
Risk group
Deaths/Patients
MRD+ MRD−
Statistics
(O−E) Var
MRD status post course 1
HR (95% CI)
(MRD+ : MRD−)
Cytogenetics:
CBF 20/74 8/82 7.7 6.8
3.08 (1.46 to 6.52)
Intermediate 174/386 111/322 26.8 70.8 1.46 (1.16 to 1.84)
Adverse 63/87 16/27 1.8 13.5 1.14 (0.67 to 1.94)
Subtotal: 257/547 135/431 36.2 91.2
1.49 (1.21 to 1.83)
2P = .001
Test for heterogeneity between subgroups: 22 = 4.6; P = .1; NS
AML17:
2.39 (1.27 to 4.50)
1.75 (1.31 to 2.35)
1.14 (0.84 to 1.55)
Good risk 26/85 13/86 8.3 9.6
Standard risk 111/267 69/253 25.0 44.6
Poor risk 132/217 56/102 5.4 41.2
Subtotal: 269/569 138/441 38.8 95.4
1.50 (1.23 to 1.84)
2P = .001
Test for heterogeneity between subgroups: 22 = 6.2; P = .04
0.0 0.5 1.0 1.5 2.0
MRD+
better
MRD−
better
A
Risk group
Deaths/Patients
B
MRD+ MRD−
Statistics
(O−E) Var
HR (95% CI)
(MRD+ : MRD−)
MRD status post course 2
Cytogenetics:
CBF 4/18 17/94 1.0 2.5
1.49 (0.44 to 5.10)
Intermediate 112/208 119/349 32.8 51.8
1.88 (1.43 to 2.47)
Adverse 43/59 17/36 6.7 14.2
1.60 (0.95 to 2.69)
Subtotal: 159/285 153/479 40.5 68.6
1.80 (1.42 to 2.29)
2P < .001
Test for heterogeneity between subgroups: 22 = 0.4; P = 0.8; NS
AML17:
Good risk 11/30 18/102 5.1 4.6
3.02 (1.22 to 7.52)
Standard risk 63/131 76/267 21.9 28.7
2.14 (1.49 to 3.09)
Poor risk 93/141 66/132 14.5 39.6
1.44 (1.06 to 1.97)
Subtotal: 167/302 160/501 41.5 73.0
1.77 (1.41 to 2.22)
2P < .001
Test for heterogeneity between subgroups: 22 = 4.0; P = .1; NS
0.0 0.5 1.0 1.5 2.0
MRD+
better
MRD−
better
Test for trend between subgroups: 21 = 6.2; P = .01
Test for trend between subgroups: 21 = 3.7; P = .05
Test for trend between subgroups: 21 = 0.1; P = .7; NS
Test for trend between subgroups: 21 = 4.0; P = .05
Fig 2. Forest plots for overall survival by
multiparametric ﬂow cytometry-MRD sta-
tus for patients in complete remission. (A)
After course 1. (B) After course 2, stratiﬁed
by cytogenetic risk group and NCRI AML17
risk score group. CBF, core binding factor;
HR, hazard ratio;MRD,measurable residual
disease; NS, not signiﬁcant; O-E, observed
minus expected; Var, variance.
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three post-C1 response categories could be proposed: RD, PR (MFC-
MRD+ whether below or above 5% blast threshold), and CR/CRi
without MRD. CRi was an independent risk factor to MRD in
a study that included patients with relapsed or refractory AML and
differing induction intensities.29,30 From our data, outcomes for
patients newly diagnosed with AML achieving negative MRD are
equivalent between CRi and CR after a single standard induction.
However, the relatively few patients in our cohort (4.8%) with both
CRi and MRD positivity after C1 had as poor survival (OS, 19% for
all;, 25% forNPM1-wt patients at standard risk) as patients with RD.
For those completing a second induction with a CR/CRi,
MRD status after C2 increased prognostic discrimination. Al-
though sample attrition bias may limit analyses comparing time
points, MRD negativity post-C2 improved outcome overall even
when adjusting for slower blast clearance by C1 response. This
differs from our previous results in older adults17 and might reﬂect
the better treatment tolerance and mutation proﬁles of younger
adults. However, after the second daunorubicin/cytosine arabi-
noside induction, approximately 33% of patients at standard risk
and approximately 34% of NPM1-wt patients at standard risk in
CR/CRi had persistent BM MRD by our assay. Whether detectable
MFC-MRD after completion of conventional induction is a sufﬁ-
ciently speciﬁc prognostic surrogate to guide therapy has been
debated. The postconsolidation time point was more informative
in the GIMEMA (Gruppo Italiano Malattie Ematologiche del-
l’Adulto) study for a cohort of which approximately 70% had
intermediate cytogenetics.31,32 This suggests that in a proportion of
those with postinduction MRD positivity, consolidation may
confer a favorable outcome by additional MFC-MRD clearance
(although it is of note that for some younger adults in the
GIMEMA trials, the induction/consolidation regimen comprised
two courses in total). Genetic proﬁle, treatment intensity, and the
later effects of any transplant may also modify interpretation and
utility of MFC-MRD to inform postremission therapy. Our data
are consistent with this because the prognostic effect as well as best
MFC-MRD cutoff level differed between AML risk groups; MRD
status appeared less discriminatory in the patients at poor risk.
Importantly, however, in the NPM1-wt standard-risk subgroup,
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Fig 3. Forest plots for (A) overall survival
and (B) relapse by combined response data
after courses 1 and 2. Effect of multi-
parametric ﬂow cytometry-MRD status in
CR after course 2 stratiﬁed by post-C1 re-
sponse status. C1, course 1; CR, complete
remission; HR, hazard ratio; MRD, mea-
surable residual disease; NS, not signiﬁ-
cant; O-E, observed minus expected; PR,
partial remission; RD, resistant disease;
Var, variance.
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detectable MFC-MRD at$ 0.1% early in treatment was associated
with signiﬁcantly higher relapse rates (89% after C2). The false-
negative 50% CIR observed for postinduction MFC-MRD negative
patients in the NPM1-wt, standard-risk subgroup could reﬂect
MFC-MRD sensitivity limitations, although a similar CIR was
observed for patients with DNTM3A/NPM1 mutations who were
MRD negative by NPM1-mutated transcript RT-qPCR.23 Ex-
ploratory analyses could not identify any signiﬁcant clinical pa-
rameters that predicted MRD2 relapses. Longitudinal, broad
molecular studies may disclose whether increased preleukemic
instability reinitiating AML33,34 or persistence of pretreatment
minor or major leukemic clones35,36 contributes to these false-
negative relapse risks. Notwithstanding, NPM1-wt patients at
standard risk who achieved MRD negativity post-C2 had signif-
icantly better survival rates. Because their survival rate increased to
88% when censored for transplant, there is the possibility that
transplant in ﬁrst remission could be avoided in this subset. The
Mantel-Byar analysis supports this with some evidence of interaction,
although this should be interpreted cautiously because of the small
number of patients and the interaction was not signiﬁcant.
Transplant decisions have mainly been arbitrary in this
subgroup, with no accepted approach to distinguish those patients
likely to be cured with chemotherapy alone (or those whose re-
sponse is likely to be successful after salvage therapy if they do
relapse) from those who beneﬁt from transplantation in ﬁrst re-
mission or potentially experimental therapy. Our results sug-
gest that allogeneic transplant in ﬁrst remission could be directed
to those who are MRD+ rather than MRD2. This is the ﬁrst
indication that MRD status might have utility in directing therapy
for NPM1-wt patients at standard risk despite their molecular
heterogeneity. Large patient data sets likely requiring collaborative
efforts will determine whether integrating MFC-MRD status with
genomic proﬁles37,38 further informs outcome prediction.
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Fig 4. Standard-risk NPM1-wild type. (A) Cumulative incidence of relapse by MRD level. (MRD2 v MRD+ , 0.1% v MRD+ $ 0.1%) after courses 1 and 2. (B) Overall
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Fig A1. Flowchart of treatments given to patients in the NCRI AML17 trial. (A) Pre-October 2011 (induction gemtuzumab ozogamicin randomization). (B) Post-October
2011 (daunorubicin dose randomization in induction). Note: patients who did not satisfy the hepatic entry criteria (liver function, 23 ULN) in (A) were allocated ADE; until
June, 2010 the consolidation randomizationwasMACE vsMACE/MidAC; the DA dose randomizationwas closed in October, 2013, and patients subsequently received DA
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October, 2012. All core binding factor (CBF) leukemias were eligible for gemtuzumab ozogamicin and were given 3 mg/m2 with course 2 if they did not receive it by
gemtuzumab ozogamicin randomization with course 1. From June, 2012 patients with informative real-time quantitative polymerase chain reaction (RT-qPCR) MRD
markers could enter the ‘Monitor vs noMonitor’ randomization that investigates the impact of serial RT-qPCRmonitoring post completion of treatment on outcome, quality
of life and health economics. ADE, cytarabine, daunorubicin, and etoposide; APL, acute promyelocytic leukemia; CBF, core binding factor; CEP-701, lestaurtinib; DA,
daunorubicin and cytarabine; GO, gemtuzumab ozogamicin (3 or 6 mg/m2); FLAG-Ida, ﬂudarabine, cytarabine, GCSF, and idarubicin; FLT3, FMS-like tyrosine kinase-3;
mTOR, everolimus; R, randomization.
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Freeman et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on April 6, 2018 from 147.188.108.163
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Patients in study
(N = 2,450)
Patients with C1 and C2 data
(n = 693)
Patients with diagnostic LAIP
(n = 1,874)
No diagnostic data
No LAIP found
Diagnostic sample
missed or inadequate
(n = 576)
(n = 102)
(n = 269/205)
After
C2 
Excluded from C2 MRD analysis
Dead by day 60
Not in remission
after C2
No response data
CR no C2 MRD data  
(n = 114)
(n = 177)
(n = 235)
(n = 1118)
MRD positive
Not in remission 
after C1
Positive after C1
Negative after C1
No after C1 data    
(n = 303)
(n = 61)
(n = 170)
(n = 24)
(n = 48)
MRD negative
Not in remission
after C1
Positive after C1
Negative after C1
No after C1 data     
(n = 503)
(n = 48)
(n = 166)
(n = 224)
(n = 65)
After
C1 
MRD+
Diagnostic LAIP
No diagnostic data
(n = 577)
(n = 493)
(n = 80)
Excluded from C1 response analysis
Dead by day 30
No response data*
CR no C1 MRD data
(n = 63)
(n = 265)
(n = 679)
Not in CR
Resistant disease
Partial remission
(n = 420)
(n = 197)
(n = 223)
MRD –
(n = 446)
Fig A2. CONSORT diagram. Outline of patient sample ﬂow for MRD study. (*) Includes patients for whom remission status could not be classiﬁed as exact timing of any
remission was unavailable. CR, complete remission; C1, course 1, C2, course 2. LAIP, leukemia-associated–immunophenotype.
jco.org © 2018 by American Society of Clinical Oncology
MFC-MRD and Response Criteria in AML Risk Groups
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on April 6, 2018 from 147.188.108.163
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Time Since Entry (years)
B
1 2 3 4 50
25
50
75
100
OS
 (%
)
No. at risk:
CR/CRi, MRD− 111 96 67 44 25 16
CR/CRi, MRD+ 149 125 76 46 24 11
PR 27 20 14 11 7 2
RD 34 20 12 2 0 0
No.
Patients
No.
Events
CR/CRi, MRD− 111 32
CR/CRi, MRD+ 149 66
PR 27 13
RD 34 22
P < .001
59%
47%
38%
28%
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
C
No.
Patients
No.
Events
CR/CRi, MRD− 111 16
CR/CRi, MRD+ 149 36
PR 27 6
RD 34 14
0 1 2 3 4 5
25
50
75
100
OS
 (%
)
Time Since Entry (years)
71%
52%
53%
28%
No. at risk:
CR/CRi, MRD− 70 42 23 12 9
CR/CRi, MRD+ 94 29 19 8 3
PR 8 5 4 3 2
RD 4 2 0 0 0
P < .001
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
Time Since Entry (years)
A
0 1 2 3 4 5
25
50
75
100
OS
 (%
)
73%
49%
41%
11%
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
No. at risk:
CR/CRi, MRD− 446 277 176 114 71 43
CR/CRi, MRD+ 575 304 131 74 39 16
PR 197 43 22 14 10 6
RD 221 24 8 2 2 1
CR/CRi, MRD−
CR/CRi, MRD+
PR
RD
No.
Patients
446
573
197
221
No.
Events
79
158
51
103
P < .001
Fig A3. OS according to response status after course 1. (A) All patients. OS censored at allogeneic SCT. (B) NPM1–wild-type patients at standard risk. (C) NPM1–wild-
type patients at standard risk, censored at allogeneic SCT. CR, complete remission; MRD, measurable residual disease; OS, overall survival; PR, partial remission; RD,
resistant disease; SCT, stem-cell transplantation.
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Fig A4. Forest plots for relapse by multiparametric ﬂow cytometry-MRD status for patients in CR (A) after course 1 and (B) after course 2 stratiﬁed by cytogenetic risk
group and NCRI AML 17 risk score group. CR, complete remission; MRD, measurable residual disease.
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Fig A5. Cumulative incidence of relapse by multiparametric ﬂow cytometry -MRD level. (MRD2 v MRD+ , 0.1% v MRD+ $ 0.1%) after course 1. (A) CBF AML. (B)
Standard-risk NPM1 mutant. AML, acute myeloid leukemia; CBF, core binding factor; MRD, measurable residual disease; MRD , 0.1%, MRD+ , 0.1%; MRD 0.1%+,
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tiparametric ﬂow cytometry-MRD status after course 2, censored at any allogeneic
stem-cell transplantation. CR, complete remission; MRD, measurable residual
disease.
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Fig A7. OS according to response status after course 1, applying European LeukemiaNet (ELN)/Cheson criteria for PR and RD instead ofMRC criteria. (ELN criteria for PR:
all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25% with decrease of pretreatment bone marrow blast percentage by $ 50%. (A) All
patients. (B) Patients at good and standard risk (patients known to be at poor risk excluded). (C) Patients at standard risk. (D) Patients at standard risk, OS censored at
allogeneic SCT. CR, complete remission; MRD, measurable residual disease; OS, overall survival; PR, partial remission; RD, resistant disease; SCT, stem-cell
transplantation.
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Table A1. Genetic Characteristics of C1 MFC-MRD- / C2 MFC-MRD+ Patients
Karyotype Cytogenetic Risk Group NPM1 Mutation Flt3 ITD
46,XY,t(8;21)(q22;q22)[7]/47,idem,+8[3] Good Negative Negative
46,XY[20] Intermediate NA NA
46,XY[20] Intermediate Positive Positive
46,XY[20] Intermediate Positive Positive
46,XX[16] Intermediate Positive Positive
46,XX[20] Intermediate Negative Positive
46,XY[20] Intermediate Negative Positive
46,XX[20] Intermediate Positive Negative
46,XY[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XX,t(11;19)(q23;p13.1)[10] Intermediate Negative Negative
46,XY,del(9)(q?2q?3)[9]/46,XY[2] Intermediate Negative Negative
46,XX,t(2;9)(p22;p21)[12]/46,XX[1] Intermediate Negative Negative
46,XY,t(6;9)(p23;q24)[9]/46,XY[1] Intermediate Negative Negative
46,XY[20] Intermediate Negative Negative
45,XX,dic(17;18)(p11.2;p11.2)[9]/46,XX[1] Intermediate Negative Negative
46,XX[20] Intermediate Negative Negative
46,XY[20] Intermediate Negative Negative
47,XY,+8[6]/ 46,XY[4] Intermediate Negative Negative
50,XY,+X,+4,t(10;11)(p12;q14),+15,+19[9]/ 46,XY[1] Adverse Negative Negative
Failed NA Negative Negative
Failed NA Negative Negative
Abbreviations: ITD, internal tandem duplication; NA, not applicable.
Table A2. Correlation of Risk Group and Clinical Response by Combined Course 1 and 2 Response Status
Risk Group Total
C1 MRD2/
C2 MRD2
C1 MRD2/
C2 MRD+
C1 MRD+/
C2 MRD2
C1 MRD+/
C2 MRD+
C1 PR/
C2 MRD2
C1 PR/
C2 MRD+
C1 RD/
C2 MRD2
C1 RD/
C2 MRD+
All (patients with both
C1 and C2 data)
693 224 (32.3) 24 (3.5) 166 (24.0) 170 (24.5) 26 (3.8) 33 (4.8) 22 (3.2) 28 (4.0)
Post-C1 risk score
Good 110 (15.9) 48 (21.4) 2 (8.3) 34 (20.5) 19 (11.2) 2 (7.7) 3 (9.1) 1 (4.5) 1 (3.6)
Standard 347 (50.1) 133 (59.4) 15 (62.5) 87 (52.4) 87 (51.2) 12 (46.2) 4 (12.1) 6 (27.3) 3 (10.7)
Poor risk 234 (33.4) 41 (18.3) 7 (29.2) 45 (27.1) 64 (37.6) 12 (46.2) 26 (78.8) 15 (68.2) 24 (85.7)
Not assessable 2 (0.3) 2 (0.9) 0 0 0 0 0 0 0
NPM1wtstandard risk 180 (26) 59 (26.3) 10 (41.2) 50 (30.1) 43 (25.3) 8 (30.8) 4 (12.1) 6 (27.3) 3 (10.7)
Post-C1 response
CR (excluding CRi) 538 (77.6) 202 (90.2) 23 (95.8) 157 (94.6) 156 (91.8)
CRi 46 (6.6) 22 (9.8) 1 (4.2) 9 (5.4) 14 (14.4)
NOTE: Data given as No. (%) unless otherwise indicated.
Abbreviations: C1, course 1; C2, course 2; CR, complete remission; CRi, complete remission with absolute neutrophil count , 1,000/mL or thrombocytopenia
, 100,000/mL; MRD, measurable residual disease; RD, resistant disease (, 50% reduction in blast numbers with. 15% residual blasts); PR, partial response ($ 50%
reduction in blast numbers with 5% to 15% residual blasts); wt, wild type.
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Table A3. Outcomes for Patients by Peripheral Count Recovery Response Combined With MRD Status
MRD status No. (%CRi) 5-Year (3-year) OS P 5-Year (3-year) CIR P
All patients
Post-C1
CR v CRi 933/88 (9.4) 53 v 39 (60 v 46) .002 50 v 43 (46 v 40) .6
MRD- CR v MRD- CRi 407/39 (9.6) 63 v 63 (70 v 63) .2 40 v 33 (35 v 33) .7
MRD+ CR v MRD+ CRi 528/9 (9.3) 45 v 19 (52 v 33) .001 58 v 53 (54 v 47) .6
Post-C2
CR v CRi 716/89 (12.4) 54 v 38 (59 v 46) .02 51 v 47 (48 v 44) .9
MRD- CR v MRD- CRi 449/54 (12.0) 63 v 52 (68 v 52) .05 61 v 57 (59 v 57) .9
MRD+ CR v MRD+ CRi 267/35 (13.1) 37 v 20 (46 v 40) .3 45 v 40 (41 v 36) .9
Standard risk NPM1 wt
Post-C1
CR v CRi 241/19 (7.9) 52 v 42 (64 v 56) .16 58 v 66 (53 v 66) .2
MRD- CR v MRD- CRi 100/11 (11.0) 60 v 64 (77 v 64) .2 49 v 66 (41 v 66) .07
MRD+ CR v MRD+ CRi 141/8 (5.7) 48 v 25 (55 v 50) .4 65 v 69 (61 v 69) .8
Post-C2
CR v CRi 180/24 (13.3) 54 v 47 (63 v 47) .3 58 v 43 (55 v 43) .6
MRD- CR v MRD- CRi 118/16 (13.6) 63 v 61 (70 v 61) .6 52 v 34 (48 v 34) .5
MRD+ CR v MRD+ CRi 62/8 (12.9) 35 v 23 (50 v 23) .10 70 v 67 (70 v 67) .7
Abbreviations: C1, course 1; C2, course 2; CIR, cumulative incidence of relapse; CR, complete remission; CRi, complete remission with absolute neutrophil count
, 1,000/mL or thrombocytopenia , 100,000/mL; MRD, measurable residual disease; NPM1, nucleophosmin. OS, overall survival; wt, wild type.
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